Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD

Beijing Anlong Biopharmaceutical Co., Ltd.

Status: Enrolling

Conditions: Wet Age-related Macular Degeneration (wAMD)

Study type: Observational

Funder types: Industry

Identifiers

NCT06718816

AL-001-LT

Details and patient eligibility

About

This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.

Enrollment: 21 estimated patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection.
• The subject or their legal representative agrees to participate in this study and signs a written ICF.
• The subjects are willing and able to follow planned visits and procedures.

Exclusion criteria

• None

Trial design

21 participants in 1 patient group

The subjects received AL-001 ophthalmic injection

Description:

Evaluate long-term safety and efficacy